Teva director granted 7,242 restricted share units

Nisen Perry reported acquisition or exercise transactions in this Form 4 filing.

Accepted by SEC EDGAR 06/01/2026 - 04:13 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Nisen Perry reported acquisition or exercise transactions in this Form 4 filing.

Teva Pharmaceutical Industries director Nisen Perry received a grant of 7,242 restricted share units. The award was granted on May 28, 2026 and will fully vest on May 28, 2027. Each restricted share unit gives a contingent right to one ordinary share or, at the committee’s option, the cash value of one ordinary share, which may be represented by American Depositary Shares.

Insider Trade Summary

Grant/Award: 7,242 shares

Grant/Award 1 txn

Insider Nisen Perry

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Restricted Share Units	7,242	$0.00	$0.00

Holdings After Transaction: Restricted Share Units — 7,242 contracts (Direct)

Footnotes (3)

1. F1. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
2. F2. Restricted share units were granted on May 28, 2026 and vest on May 28, 2027.
3. F3. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Key Figures

RSUs granted: 7,242 units Grant price: $0.00 per unit Underlying shares: 7,242 ordinary shares +4 more

7 metrics

RSUs granted 7,242 units Restricted share units granted on May 28, 2026

Grant price $0.00 per unit Compensation award, not open-market purchase

Underlying shares 7,242 ordinary shares Shares underlying the restricted share units

Post-transaction RSU holdings 7,242 units Total restricted share units following the transaction

Grant date May 28, 2026 Date RSUs were awarded

Vesting date May 28, 2027 Date RSUs vest

ADS ratio 1 ADS = 1 ordinary share Representation of Teva ordinary shares

Key Terms

Restricted Share Units, contingent right, American Depositary Shares, Human Resources and Compensation Committee

4 terms

Restricted Share Units financial

"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or cash."

Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.

contingent right financial

"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or cash."

American Depositary Shares financial

"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

Human Resources and Compensation Committee financial

"At the option of the Human Resources and Compensation Committee, the award may be settled in cash."

A board-level committee that oversees a company’s pay and personnel policies, including executive compensation, employee benefits, hiring, leadership development and succession planning. It matters to investors because the committee shapes incentives, labor costs and management continuity—factors that affect performance, risk and shareholder value—like a coach setting rules and pay that influence how a team performs.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did TEVA director Nisen Perry report on this Form 4?

Nisen Perry reported receiving 7,242 restricted share units as an equity award. The units were granted at a price of $0.00 per unit and represent a compensation-related acquisition rather than an open-market purchase or sale of Teva shares.

When do Nisen Perry’s 7,242 TEVA restricted share units vest?

The 7,242 restricted share units granted to Nisen Perry vest on May 28, 2027. Vesting means that on this date, the units convert into the right to receive Teva ordinary shares or their cash value, subject to the plan’s terms.

What does each restricted share unit represent for TEVA’s Nisen Perry grant?

Each restricted share unit represents a contingent right to receive one Teva ordinary share or, at the Human Resources and Compensation Committee’s option, the cash value of one ordinary share, providing equity-based compensation rather than immediate share ownership.

How many TEVA shares underlie Nisen Perry’s new restricted share units?

The 7,242 restricted share units are linked to 7,242 underlying Teva ordinary shares. Upon settlement after vesting, the award may deliver ordinary shares or their cash equivalent, depending on how the compensation committee decides to settle the award.

Are TEVA American Depositary Shares involved in Nisen Perry’s Form 4 award?

The filing states that Teva’s ordinary shares may be represented by American Depositary Shares, with each ADS currently representing one ordinary share. This means settlement of the restricted share units could be reflected through ADS, consistent with this one-for-one relationship.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Nisen Perry

(Last) (First) (Middle)

C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.

124 DVORA HANEVI'A ST.,

(Street)

TEL AVIV ISRAEL 6944020

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
TEVA PHARMACEUTICAL INDUSTRIES LTD [ TEVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Share Units	(1)	05/28/2026		A		7,242		(2)	(2)	Ordinary Shares(3)	7,242	$0	7,242	D

Explanation of Responses:

1. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

2. Restricted share units were granted on May 28, 2026 and vest on May 28, 2027.

3. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

	/s/ Dov Bergwerk as attorney-in-fact for Perry D. Nisen	06/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)